Back to Search
Start Over
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
- Source :
-
Annals of surgical oncology [Ann Surg Oncol] 2015 Oct; Vol. 22 (11), pp. 3653-8. Date of Electronic Publication: 2015 Feb 18. - Publication Year :
- 2015
-
Abstract
- Background: We performed a prospective, multi-institutional, phase-II, clinical trial of a docetaxel, nedaplatin, and 5-fluorouracil (DNF) regimen in patients with unresectable esophageal cancer. Our goal was to determine the efficacy and feasibility of this DNF protocol.<br />Methods: Thirty-four patients with unresectable esophageal cancer were enrolled and received DNF therapy. The DNF regimen was repeated every 4 weeks for up to 8 weeks, based on the following recommended doses: docetaxel, 60 mg/m(2) (day 1); nedaplatin, 70 mg/m(2) (day 1); and 5-fluorouracil, 700 mg/m(2) (days 1-5). The primary endpoint was the response rate. The secondary endpoints were overall survival and chemotherapy toxicities.<br />Results: The complete response rate and response rate were 5.9 and 47.1 %, respectively. The 2-year overall survival rate and progression-free survival rate were 44.3 and 27.3 %, respectively. The median survival time was 594 days. The median progression-free time was 277 days. No treatment-related deaths occurred. Thirty patients (30/34) with grade 3, 4 neutropenia improved relatively quickly with administration of granulocyte colony-stimulating factor.<br />Conclusions: DNF combination chemotherapy is a useful regimen with relatively minor adverse events and may serve as an effective protocol in patients with unresectable esophageal cancer.
- Subjects :
- Adenocarcinoma secondary
Adenocarcinoma therapy
Aged
Antineoplastic Combined Chemotherapy Protocols adverse effects
Carcinoma, Squamous Cell secondary
Carcinoma, Squamous Cell therapy
Chemoradiotherapy
Disease-Free Survival
Docetaxel
Esophageal Neoplasms pathology
Esophageal Neoplasms therapy
Esophagectomy adverse effects
Female
Fluorouracil administration & dosage
Granulocyte Colony-Stimulating Factor therapeutic use
Humans
Lung Neoplasms secondary
Lymph Node Excision
Lymphatic Metastasis
Male
Middle Aged
Neutropenia chemically induced
Neutropenia drug therapy
Organoplatinum Compounds administration & dosage
Prospective Studies
Survival Rate
Taxoids administration & dosage
Treatment Outcome
Adenocarcinoma drug therapy
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Carcinoma, Squamous Cell drug therapy
Esophageal Neoplasms drug therapy
Lung Neoplasms surgery
Subjects
Details
- Language :
- English
- ISSN :
- 1534-4681
- Volume :
- 22
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Annals of surgical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 25691281
- Full Text :
- https://doi.org/10.1245/s10434-015-4440-4